Do analysts rate TCRT or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, TCRT or QNTM?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is TCRT or QNTM more profitable?

Alaunos Therapeutics' return on equity of -165.94% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Quantum Biopharma N/A -941.54% -224.41%

Do analysts rate QNTM or XLO?

Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 210.77%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts rate QNTM or IMMP?

Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,318.26%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, QNTM or IMMP?

Quantum Biopharma has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A Prima BioMed $6.69M 8.54 -$39.78M N/A N/A

Is QNTM or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -941.54% -224.41% Prima BioMed N/A N/A N/A

Does the media prefer QNTM or IMMP?

In the previous week, Prima BioMed had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 7 mentions for Prima BioMed and 3 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.56 beat Prima BioMed's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MCRB or QNTM?

Seres Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 149.08%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Seres Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MCRB or QNTM more profitable?

Seres Therapeutics' return on equity of -130.29% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Quantum Biopharma N/A -941.54% -224.41%

Do analysts rate TIL or QNTM?

Instil Bio presently has a consensus target price of $66.00, indicating a potential upside of 763.87%. Given Instil Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Instil Bio is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, TIL or QNTM?

Instil Bio is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is TIL or QNTM more profitable?

Instil Bio's return on equity of -39.76% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Quantum Biopharma N/A -941.54% -224.41%

Quantum Biopharma (QNTM) Competitors

$3.91 +0.06 (+1.56%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$4.00 +0.09 (+2.40%)

As of 06/24/2026 07:59 PM Eastern

Compare

QNTM vs. TCRT, XLO, IMMP, MCRB, and TIL

Should you buy Quantum Biopharma stock or one of its competitors? MarketBeat compares Quantum Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quantum Biopharma include Alaunos Therapeutics (TCRT), Xilio Therapeutics (XLO), Prima BioMed (IMMP), Seres Therapeutics (MCRB), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry.

How does Quantum Biopharma compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

In the previous week, Quantum Biopharma had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Alaunos Therapeutics. Quantum Biopharma's average media sentiment score of 0.56 beat Alaunos Therapeutics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
Quantum Biopharma	Positive

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alaunos Therapeutics has a beta of -1.07, suggesting that its stock price is 207% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

Alaunos Therapeutics' return on equity of -165.94% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Quantum Biopharma	N/A	-941.54%	-224.41%

Summary

Alaunos Therapeutics beats Quantum Biopharma on 6 of the 10 factors compared between the two stocks.

How does Quantum Biopharma compare to Xilio Therapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Quantum Biopharma had 3 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Xilio Therapeutics. Quantum Biopharma's average media sentiment score of 0.56 beat Xilio Therapeutics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Quantum Biopharma	Positive
Xilio Therapeutics	Neutral

Quantum Biopharma has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$3.55	N/A

Quantum Biopharma has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 210.77%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Xilio Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Quantum Biopharma has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

Summary

Xilio Therapeutics beats Quantum Biopharma on 8 of the 15 factors compared between the two stocks.

How does Quantum Biopharma compare to Prima BioMed?

Quantum Biopharma (NASDAQ:QNTM) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Quantum Biopharma has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Prima BioMed	$6.69M	8.54	-$39.78M	N/A	N/A

Prima BioMed's return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Prima BioMed	N/A	N/A	N/A

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,318.26%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Prima BioMed had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 7 mentions for Prima BioMed and 3 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.56 beat Prima BioMed's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quantum Biopharma has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

Summary

Prima BioMed beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks.

How does Quantum Biopharma compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, Seres Therapeutics had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 7 mentions for Seres Therapeutics and 3 mentions for Quantum Biopharma. Seres Therapeutics' average media sentiment score of 1.13 beat Quantum Biopharma's score of 0.56 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Seres Therapeutics	Positive
Quantum Biopharma	Positive

Seres Therapeutics has higher revenue and earnings than Quantum Biopharma. Seres Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	83.63	$5.70M	-$5.17	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Seres Therapeutics has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Seres Therapeutics' return on equity of -130.29% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Quantum Biopharma	N/A	-941.54%	-224.41%

Seres Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 149.08%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Seres Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Seres Therapeutics beats Quantum Biopharma on 11 of the 14 factors compared between the two stocks.

How does Quantum Biopharma compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Instil Bio's return on equity of -39.76% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Quantum Biopharma	N/A	-941.54%	-224.41%

Instil Bio has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

In the previous week, Quantum Biopharma had 3 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Instil Bio. Quantum Biopharma's average media sentiment score of 0.56 beat Instil Bio's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Instil Bio	Neutral
Quantum Biopharma	Positive

Instil Bio is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Instil Bio presently has a consensus target price of $66.00, indicating a potential upside of 763.87%. Given Instil Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Instil Bio is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Instil Bio beats Quantum Biopharma on 8 of the 12 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNTM vs. The Competition

Export

Metric	Quantum Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.69M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.47	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	2.92	8.26	10.76	6.41
Net Income	-$26.17M	$23.91M	$3.56B	$337.14M
7 Day Performance	2.89%	2.12%	0.98%	-1.06%
1 Month Performance	-57.68%	2.40%	0.78%	0.49%
1 Year Performance	-83.96%	57.09%	30.24%	28.43%

Quantum Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNTM Quantum Biopharma	0.2464 of 5 stars	$3.91 +1.6%	N/A	-85.6%	$14.69M	N/A	N/A	N/A	News Coverage
TCRT Alaunos Therapeutics	0.2413 of 5 stars	$2.24 -1.8%	N/A	-56.2%	$55.68M	N/A	N/A	40	Gap Up
XLO Xilio Therapeutics	2.091 of 5 stars	$8.25 -1.1%	$28.00 +239.4%	-2.5%	$54.84M	$43.77M	N/A	70
IMMP Prima BioMed	1.8617 of 5 stars	$0.36 -3.8%	$5.50 +1,444.1%	-75.8%	$54.57M	$4.08M	N/A	2,021
MCRB Seres Therapeutics	2.4746 of 5 stars	$5.97 +6.2%	$22.00 +268.5%	-18.9%	$54.42M	$1.15M	N/A	330	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNTM) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum Biopharma (QNTM) Competitors

QNTM vs. TCRT, XLO, IMMP, MCRB, and TIL

How does Quantum Biopharma compare to Alaunos Therapeutics?

Summary

How does Quantum Biopharma compare to Xilio Therapeutics?

Summary

How does Quantum Biopharma compare to Prima BioMed?

Summary

How does Quantum Biopharma compare to Seres Therapeutics?

Summary

How does Quantum Biopharma compare to Instil Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum Biopharma (QNTM) Competitors

QNTM vs. TCRT, XLO, IMMP, MCRB, and TIL

How does Quantum Biopharma compare to Alaunos Therapeutics?

Does the media refer more to TCRT or QNTM?

Which has preferable valuation & earnings, TCRT or QNTM?

Do insiders & institutionals hold more shares of TCRT or QNTM?

Do analysts rate TCRT or QNTM?

Which has more volatility & risk, TCRT or QNTM?

Is TCRT or QNTM more profitable?

Summary

How does Quantum Biopharma compare to Xilio Therapeutics?

Do insiders & institutionals believe in QNTM or XLO?

Does the media favor QNTM or XLO?

Which has stronger earnings & valuation, QNTM or XLO?

Is QNTM or XLO more profitable?

Do analysts rate QNTM or XLO?

Which has more risk and volatility, QNTM or XLO?

Summary

How does Quantum Biopharma compare to Prima BioMed?

Which has better valuation and earnings, QNTM or IMMP?

Is QNTM or IMMP more profitable?

Do insiders & institutionals believe in QNTM or IMMP?

Do analysts rate QNTM or IMMP?

Does the media prefer QNTM or IMMP?

Which has more risk and volatility, QNTM or IMMP?

Summary

How does Quantum Biopharma compare to Seres Therapeutics?

Does the media refer more to MCRB or QNTM?

Which has better earnings and valuation, MCRB or QNTM?

Which has more risk & volatility, MCRB or QNTM?

Do institutionals & insiders have more ownership in MCRB or QNTM?

Is MCRB or QNTM more profitable?

Do analysts recommend MCRB or QNTM?

Summary

How does Quantum Biopharma compare to Instil Bio?

Do institutionals and insiders have more ownership in TIL or QNTM?

Is TIL or QNTM more profitable?

Which has more risk & volatility, TIL or QNTM?

Does the media refer more to TIL or QNTM?

Which has better valuation & earnings, TIL or QNTM?

Do analysts rate TIL or QNTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools